Format

Send to

Choose Destination
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Collaborators (327)

Fein L, Kaen L, Lerzo G, Egle D, Greil R, Hubalek M, Singer C, Steger G, Dirix L, Duhoux F, Jerusalem G, Renard V, Araujo R, Boukai A, Hegg R, Lima JP, Mano M, Morelle A, Muller AP, Paiva CE, Pedrini JL, Pinczowski H, Santos L, Teich NL, Testa L, Wiermann E, Basik M, Davidson JA, Goel R, Logan D, Lohrisch C, Mackey J, Martin LA, Paterson A, Prady C, Provencher L, Robidoux A, Sridhar S, Thirlwell M, Tonkin K, Warr D, Li W, Liao N, Pang D, Shao Z, Shen K, Wang S, Wang Y, Franco S, Gonzalez M, Quiroga Echeverri A, Yepes A, Kubala E, Melichar B, Paulik A, Zimovjanova M, Bonnefoi H, Bourgeois H, Brain E, Curtit E, D'Hondt V, Dieras V, Espie M, Extra JM, Gligorov J, Grenier J, Levy C, Mouret-Reynier MA, Nabholtz JM, Orfeuvre H, Petit T, Pierga JY, Pivot X, Romieu G, Saghatchian-D'Assignies M, Teixeira L, Thery JC, Veyret C, Aktas B, Bauer S, Belau A, Blohmer JU, Eidtmann H, Fasching P, Fehm T, Feisel-Schwickardi G, Fischer HH, Gerteis A, Grafe A, Graffunder G, Grischke EM, Hackmann J, Harbeck N, Heinrich B, Hielscher C, Hoffmann O, Jackisch C, Janni W, Just M, Klare P, Kronawitter U, Kühn T, Kümmel S, Kunz G, Lantzsch T, Lübbe K, Meinerz W, Mundhenke C, Negwer M, Neunhöffer T, Overkamp F, Park-Simon TW, Rack B, Rautenberg B, Reimer T, Rezai M, Salat C, Schem C, Schlag R, Schmatloch S, Schnappauf B, Schneeweiss A, Schrauder M, Schumacher C, Schwaner I, Solbach C, Stickeler E, Tesch H, Thalmann I, Thomssen C, Untch M, Wachsmann GT, Warm M, Wiebringhaus H, Wulfing P, Mavroudis D, Papazisis K, Castro-Salguero H, Hernandez-Monroy CE, Cheung FY, Kwong A, Ng TY, Soong SI, Coate L, Crown J, Hennessy B, Higgins M, Keane M, Kelly C, Moylan E, Nasim S, O'Reilly S, Ben Baruch N, Geffen D, Kaufman B, Rosengarten O, Uziely B, Yerushalmi R, Allegrini G, Bianchi G, Brandes A, Cazzaniga M, Cinieri S, Colleoni MA, Conte PF, De Laurentiis M, De Placido S, Del Mastro L, Fiorio E, Fontana A, Generali D, Gianni L, Marchetti P, Molino AM, Montemurro F, Rota Caremoli E, Tonini G, Zamagni C, Arce Salinas C, Chavarri Guerra Y, Hernandez CA, Lopez-Lopez F, Martinez G, Villarreal Garza CM, Alcedo JC, Lopez RI, Aleman D, Becerra J, Desposorio C, Kobashigawa A, Pimentel P, Pesic J, Stamatovic L, Coccia-Portugal M, Cullis SM, Maart K, Moodley SD, Pienaar F, Rapoport B, Alvarez Lopez I, Carabantes F, Echarri Gonzalez MJ, Fernandez Perez I, Garcia Estevez L, Illarramendi Mañas JJ, Llorente Domenech RM, Mele Olive M, Muñoz Mateu M, Redondo Sanchez A, Rodriguez Sanchez C, Ruiz Borrego M, Ruiz Simo A, Bjöhle J, Del Val Munoz O, Hatschek T, Loman N, Schreiber A, Tausch C, Chen SC, Huang CS, Liu MC, Tseng LM, Yang Y, Yeh DC, Aliustaoglu M, Cicin I, Elkiran ET, Evrensel T, Gumus M, Karabulut B, Uslu R, Yildirim ME, Adamson D, Bradley C, Braybrooke J, Chan S, Dhadda A, Joffe J, Lowdell C, Mansi J, Michie C, Mohanamurali J, Perren T, Rea D, Scatchard K, Stebbing J, Wardley A, Wheatley D, Winter M, Abraham J, Avery T, Bear HD, Boyle LE, Brufsky A, Chambers M, Chang J, Charles A, Chaudhry M, Cobleigh M, Conlin A, Constantino S, DeFusco P, DiGiovanna M, Doyle T, Farrar W, Fehrenbacher L, Flaherty L, Flynn PJ, Gayle A, Giordano S, Han H, Hantel A, Hargis J, Hershman D, Ibach D, Jaslow R, Julian T, Karwal M, Kramer R, Krie A, Krill-Jackson E, Limentani S, Link J, Mamounas E, Maurer M, McCarron E, Mehta R, Menter A, Murali S, Nguyen B, Oldham D, Padula G, Pajon E, Patel K, Paterson A, Phelan J, Polikoff J, Resta R, Rimawi M, Riseberg D, Robertson J, Romond E, Seaward S, Seeger J, Shah N, Shalaby I, Sinclair S, Steen P, Sturtz K, Tamkus D, Tan AR, Thomas A, Tolentino A, Toppmeyer D, Trehan S, Valero V, Vaughn C, Wahl T, Waisman J, Wapnir I, Weisberg TF, Wickerham DL, Yost K, Zakalik D, Zapas J, Zera R, Zhang W.

Author information

1
From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

Abstract

BACKGROUND:

Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy.

METHODS:

We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. The primary end point was invasive disease-free survival (defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause).

RESULTS:

At the interim analysis, among 1486 randomly assigned patients (743 in the T-DM1 group and 743 in the trastuzumab group), invasive disease or death had occurred in 91 patients in the T-DM1 group (12.2%) and 165 patients in the trastuzumab group (22.2%). The estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T-DM1 group and 77.0% in the trastuzumab group. Invasive disease-free survival was significantly higher in the T-DM1 group than in the trastuzumab group (hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 0.39 to 0.64; P<0.001). Distant recurrence as the first invasive-disease event occurred in 10.5% of patients in the T-DM1 group and 15.9% of those in the trastuzumab group. The safety data were consistent with the known safety profile of T-DM1, with more adverse events associated with T-DM1 than with trastuzumab alone.

CONCLUSIONS:

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hoffmann-La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472 .).

PMID:
30516102
DOI:
10.1056/NEJMoa1814017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center